Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key ...
Yahoo Finance11d
Amgen profits rise, next MariTide studies start by mid-year
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
Yahoo Finance11d
Amgen profits rise, next MariTide studies start by mid-year
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
3 Fabulous Dividend Stocks to Buy in February
AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...
The Motley Fool: An inside look at Amgen’s fall
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Amgen's SWOT analysis: stock outlook amid obesity drug race
Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...